Amersham’s Metastron (Strontium-89)
Executive Summary
Injectable cancer pain drug is being launched June 28 at a list price of $1,850 for a 4 mCi single-dose vial. One dose, delivered in an outpatient procedure, "usually is effective for an average of six months." Metastron, approved by FDA on June 18, ("The Pink Sheet" June 21, T&G-1) will be promoted to urology and medical oncology specialists by Zeneca and to nuclear medicine, radiopharmacy, and radiation oncology experts by Amersham, under a worldwide co-promotion agreement.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth